Literature DB >> 1357024

The potentiation of narcotic analgesics with phenothiazines.

P A Richter1, M P Burk.   

Abstract

Potentiation of narcotic analgesics with phenothiazines have been used for preoperative and postoperative analgesia for a number of years by the podiatric community. The agents most frequently cited in studies are the combination of meperidine with either the phenothiazines chlorpromazine, trimeprazine, or promethazine. Due to the fact that the double-blind clinical studies of pain are mainly subjective, and difficult to quantify, the usefulness of phenothiazines for the sole purpose of potentiation of analgesia is questionable, especially in view of the many side effects of this group of drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357024

Source DB:  PubMed          Journal:  J Foot Surg        ISSN: 0449-2544


  5 in total

1.  Promethazine use among chronic pain patients.

Authors:  Kara L Lynch; Brad J Shapiro; Diana Coffa; Scott P Novak; Alex H Kral
Journal:  Drug Alcohol Depend       Date:  2015-02-26       Impact factor: 4.492

2.  Promethazine misuse among methadone maintenance patients and community-based injection drug users.

Authors:  Brad J Shapiro; Kara L Lynch; Tab Toochinda; Alexandra Lutnick; Helen Y Cheng; Alex H Kral
Journal:  J Addict Med       Date:  2013 Mar-Apr       Impact factor: 3.702

3.  Comparison of the efficacy of adding clonidine, chlorpromazine, promethazine, and midazolam to morphine pumps in postoperative pain control of addicted patients.

Authors:  Farnad Imani; Poupak Rahimzadeh; Seyyed Hamid Reza Faiz
Journal:  Anesth Pain Med       Date:  2011-07-01

Review 4.  Intravenous treatment of chronic daily headaches in the outpatient headache clinic.

Authors:  John Claude Krusz
Journal:  Curr Pain Headache Rep       Date:  2006-02

5.  Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports.

Authors:  Stefania Chiappini; Fabrizio Schifano; John Martin Corkery; Amira Guirguis
Journal:  J Psychopharmacol       Date:  2021-01-10       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.